This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thomas, G. V. Articles by Sawyers, C. L. Search for Related Content PubMed PubMed Citation Articles by Thomas, G. V. Articles by Sawyers, C. L.

Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer

¹ Department of Pathology and Laboratory Medicine, ² Department of Human Genetics and Biostatistics, ³ Department of Urology, and ⁴ The Howard Hughes Medical Institute, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California; and ⁵ Cell Signaling Technologies, Beverly, Massachusetts

Purpose: As kinase inhibitors transition from the laboratory to patients, it is imperative to develop biomarkers that can be used in the clinic. The primary objectives are to identify patients most likely to benefit from molecularly targeted therapies and to document modulation of the drug target. Constitutive activation of the phosphoinositide 3-kinase (PI3K) pathway and its downstream effectors, as a result of PTEN loss or by other mechanisms, occurs in a high proportion of prostate cancers, making it an ideal template for the design of clinical trials involving PI3K pathway inhibitors. Prostate cancers also present unique organ-specific challenges, in that tumors are heterogeneous and diagnostic tissue is extremely limited.

Experimental Design: Working within these limitations, we have developed a set of immunohistochemical assays that define activation of the PI3K pathway in clinical samples.

Results and Conclusions: Using both univariate and multivariate analyses, we show that loss of PTEN is highly correlated with the activation of AKT, and this, in turn, is associated with the phosphorylation of S6, one of its main effectors. These three antibodies are potentially able to define a molecular signature of PTEN loss and/or AKT pathway activation in prostate cancer.

This article has been cited by other articles:

				T. S. Hudson, D. K. Hartle, S. D. Hursting, N. P. Nunez, T. T.Y. Wang, H. A. Young, P. Arany, and J. E. Green Inhibition of Prostate Cancer Growth by Muscadine Grape Skin Extract and Resveratrol through Distinct Mechanisms Cancer Res., September 1, 2007; 67(17): 8396 - 8405. [Abstract] [Full Text] [PDF]

				L. Ma, J. Teruya-Feldstein, P. Bonner, R. Bernardi, D. N. Franz, D. Witte, C. Cordon-Cardo, and P. P. Pandolfi Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer Cancer Res., August 1, 2007; 67(15): 7106 - 7112. [Abstract] [Full Text] [PDF]

				C. Wu and J. Huang Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Is Essential for Neuroendocrine Differentiation of Prostate Cancer J. Biol. Chem., February 9, 2007; 282(6): 3571 - 3583. [Abstract] [Full Text] [PDF]

				Z. Dong, Y. Liu, S. Lu, A. Wang, K. Lee, L.-H. Wang, M. Revelo, and S. Lu Vav3 Oncogene Is Overexpressed and Regulates Cell Growth and Androgen Receptor Activity in Human Prostate Cancer Mol. Endocrinol., October 1, 2006; 20(10): 2315 - 2325. [Abstract] [Full Text] [PDF]

				M. Hughes-Fulford, C.-F. Li, J. Boonyaratanakornkit, and S. Sayyah Arachidonic Acid Activates Phosphatidylinositol 3-Kinase Signaling and Induces Gene Expression in Prostate Cancer Cancer Res., February 1, 2006; 66(3): 1427 - 1433. [Abstract] [Full Text] [PDF]

				C.L. SAWYERS Making Progress through Molecular Attacks on Cancer Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 479 - 482. [Abstract] [PDF]